Cislini Jeff sold $337K of RVMD

Revolution Medicines (RVMD) shares rose 9.4% after reporting Q2 2026 results. Net loss widened to $644.37 million, or $3.06 loss per share, and first-half net loss totaled $1.10 billion. The company said the FDA accepted its daraxonrasib NDA for previously treated metastatic pancreatic cancer, with over 2,000 patients treated via compassionate use and $3.9 billion cash.

Revolution Medicines (RVMD) reported a wider-than-expected adjusted Q2 2026 loss of $2.34 per share versus a $1.93 consensus estimate. Including a $151 million non-cash warrant fair-value charge from its EQRx acquisition, the loss was $3.06 per share. The company raised 2026 operating expense guidance to $2.1-$2.2 billion and ended June with $3.9 billion cash.

Revolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rvmd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress · U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer followin

Revolution Medicines (RVMD) shares rose about 5.3% after the U.S. FDA accepted its daraxonrasib NDA for priority review in previously treated metastatic pancreatic ductal adenocarcinoma. The filing is based on Phase 3 RASolute 302 results, and the drug has Breakthrough Therapy and Orphan Drug designations plus National Priority Voucher inclusion. The article cites $1.6b to $1.7b operating expense guidance and forecast $1.0b revenue by 2029.

Revolution Medicines (RVMD) said the FDA accepted its NDA for daraxonrasib, an oral RAS(ON) inhibitor, for metastatic pancreatic ductal adenocarcinoma. The filing is supported by the Phase 3 RASolute 302 trial, which met primary and key secondary endpoints versus standard chemotherapy. FDA Breakthrough and orphan designations and National Priority Voucher selection were noted.

The article lists five “upside” stock calls from Wall Street. JPMorgan initiated CECO Environmental (CECO) with a $130 target, citing AI data center demand and Thermon. It also targets PRM at $50. Goldman upgraded Toast (TOST) to Buy at $36. BofA raised Ligand (LGND) target to $388. Revolution Medicines (RVMD) reported Phase 3 pancreatic cancer results for daraxonrasib, with median OS 13.2 vs 6.7 months.